OBJECTIVES: Estimating health-related utility weights in Crohn’s Disease (CD) patients is crucial for assessing the cost-effectiveness of new pharmaceutical interventions. However, values used in these analyses are usually based on secondary data and vary substantially  among studies. We estimated utility weights in a consecutive sample of real-world CD patients.  METHODS: Patients enrolled in an ongoing socio-economic study of CD in the Israeli adult patient population completed the self-administered SF-36 questionnaire and were assessed for their current clinical status, including the Harvey-Bradshaw Index (HBI) of disease severity. Patients were classified to one of the four disease states: disease remission (HBI<5); mild disease (HBI 5-7); moderate disease (HBI 8-16), and severe disease (HBI>16). For each patient enrolled we calculated a utility weight using the SF-6D preference-based scoring system developed by Brazier et al.  RESULTS: The cohort comprised of 373 patients: (39.4% male), with mean age of 37.8 (±14.2) years, 14.5 (±2.8) years of education, and 11.8 (±9.0) years elapsed since first diagnosis. The average HBI was 6.7 (± 5.6); 148 patients were in remission state, 79 had mild disease, 121 moderate and 25 severe disease. The SF-6D utility weights were correlated with the HBI (-0.341; p<0.0001). The mean utility weights for each disease state were as follows: disease remission: 0.720 (±0.141); mild disease; 0.700 (±0.123); moderate disease: 0.603 (±0.109); severe disease: 0.531 (±0.135); p<0.001. The significant predictors of utility weights in a multivariable regression analysis were the HBI (β=-0,440; p<0.001), years of education (β=0.104; p=0.034), and time since diagnosis (β=0.150; p=0.007); (R =0.246).  CONCLUSIONS: CD patients suffer from a deprived quality of life even in the remission and mild stages of the disease. Utility weights for these patients were generally lower as compared to values used in published cost-effectiveness analyses. These values should be considered when assessing the value for money of future interventions for CD